Avaleht › Melanoom › Minnesota › Minneapolis
Melanoom kliinilised uuringud linnas Minneapolis, MN
12 uuringut haiguse Melanoom jaoks otsivad osalejaid linnas Minneapolis ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi kaugusel
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
VärbamineFaas 2
- Health Partners Frauenshuh Cancer Center, Saint Louis Park · 5 mi kaugusel
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
VärbamineFaas 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi kaugusel
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
VärbamineFaas 3
- Allina Health Cancer Institute, Minneapolis
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
VärbamineFaas 3
- University of Minnesota, Minneapolis
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
VärbamineFaas 1/2
- Minnesota Oncology and Hematology PA, Minneapolis
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
VärbamineFaas 2
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- ja veel 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
VärbamineFaas 1/2
- University of Minnesota/Masonic Cancer Center, Minneapolis
Project: Every Child for Younger Patients With Cancer
VärbamineVaatlusuuring
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
VärbamineFaas 1/2
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
VärbamineVaatlusuuring
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi kaugusel
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
VärbamineFaas 3
- University of Minnesota Medical Center, Minneapolis
Melanoom uuringud teistes linnades
- Houston, TX59 uuringut
- New York City, NY38 uuringut
- Los Angeles, CA34 uuringut
- Nashville, TN33 uuringut
- Pittsburgh, PA31 uuringut
- Boston, MA26 uuringut
- Philadelphia, PA23 uuringut
- San Francisco, CA22 uuringut
- Durham, NC21 uuringut
- Atlanta, GA21 uuringut
- St. Louis, MO21 uuringut
- Salt Lake City, UT21 uuringut
Muud uuringud linnas Minneapolis
- Rinnavähk27 uuringut
- Mitteväikerakuline kopsuvähk26 uuringut
- Munasarjavähk24 uuringut
- Eesnäärmevähk23 uuringut
- Vähk (kõik liigid)22 uuringut
- Südamepuudulikkus21 uuringut
- Kopsuvähk20 uuringut
- Äge müeloidne leukeemia20 uuringut
- Käär- ja pärasoolevähk19 uuringut
- Endomeetriumivähk18 uuringut
- Parkinsoni tõbi17 uuringut
- Kardiovaskulaarsed haigused15 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.